Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vardenafil in Symptomatic BPH
NCT00657839Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Vardenafil Arm with Placebo Arm (2 arms). Primary endpoints: International Prostate Symptom Score at 8 weeks and Maximal Urinary Flow at 8 weeks. Started Oct 2005; status: completed.
02
Drugs
vardenafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00657839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00657839.